ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,179.68
-0.55%
Dow Jones
39,117.63
-0.03%
Gold vs US Dollar
2,325.895
1.20%
Brent Oil
85.09
0.73%
Bitcoin
61,812.50
1.64%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Boundless Bio Inc (BOLD) Share Price

BOLD Boundless Bio Inc

4.07
0.07 (1.75%)
Last Updated: 18:55:40
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Boundless Bio Inc NASDAQ:BOLD NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.07 1.75 4.07 4.07 4.16 4.10 3.90 4 42,293 17:55:40   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -49.43M -2.2213 -1.76 87.24M
 Type  Size  Price  Time  Units 
 9 1 4.1174 17:56:05 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore BOLD News
05/06/202412:00BWBoundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
13/05/202412:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/05/202412:05EDGAR2Form 8-K - Current report
13/05/202412:00BWBoundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
06/05/202413:00BWBoundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
11/04/202413:00BWBoundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
08/04/202413:00BWBoundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
Period
Draw mode
Data Downloads for BOLD

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Boundless Bio Inc Articles